In the first placebo-controlled trial of vaporized cannabis for acute migraine, patients experienced greater relief from pain and other symptoms than those receiving a placebo.
During a migraine attack, participants who inhaled a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) reported significant pain reduction and improvement in their most bothersome symptom within 2 hours of treatment.
The findings suggest that a THC-CBD combination may offer a viable treatment option for acute migraine in patients who do not respond to standard therapies, study investigator Nathaniel M. Schuster, MD, pain and headache neurologist and associate professor of anesthesiology at the UC San Diego (UCSD) Health Center for Pain Medicine, told Medscape Medical News.
“This is the first placebo-controlled study in this space. It’s the first real — to me — compelling evidence for the antimigraine effects of cannabis in humans,” he said.
The findings were presented here at the American Headache Society (AHS) Annual Meeting 2025.
Read the full article at Medscape
